Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Warning Letter Calls Attention to Celltrion's 'Poor' Aseptic Practices

Executive Summary

FDA warning letter to South Korean manufacturer Celltrion cites an extensive list of problems related to inadequate contamination controls and shows how companies launching biosimilars can be tripped up by GMP compliance problems.

Advertisement

Related Content

Keeping Track Of Bad News: Alkermes' Depression Candidate Gets Refuse To File; Teva/Celltrion Biosimilars Land CRLs
The New 180 Days? Humira Biosimilar Deals Give Amgen 150-Day Jump On Samsung
Teva On Tenterhooks Over Fremanezumab As Celltrion Gets CRLs
Bad News Teva Really Doesn't Need: A Potential Delay For Fremanezumab
Celltrion Biosimilar Is Latest To Run Into GMP Compliance Concerns

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS122473

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel